Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In BlackRock TCP To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in BlackRock TCP between November 6, 2024 and January 23, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information]New York, New York--(Newsfile Corp. - F ...

Opening statements began in a trial claiming social media companies design addictive products that cause personal injury. ...

Core Viewpoint - Kyndryl's shares fell over 56% intra-day following the announcement of a delay in filing its December-quarter financial report due to material weaknesses in internal controls over financial reporting [1] Group 1: Financial Reporting Issues - The identified weaknesses in internal controls extend across the fiscal year ending March 2025 and the first two quarters of fiscal 2026 [2] - Kyndryl stated that it does not expect any impact on its balance sheets, income statements, cash flow statements, or equity statements despite the identified issues [2] Group 2: Executive Changes - Kyndryl announced several executive changes, including the departure of Chief Financial Officer David Wyshner and the appointment of Harsh Chugh as interim CFO [3] - Global Controller Vineet Khurana also stepped down, with Bhavna Doegar appointed as interim corporate controller [3] Group 3: Revenue Outlook - Kyndryl released its third-quarter results and lowered its revenue outlook for fiscal 2026 [4]

To celebrate High Yield Investor turning five, we’re offering a 30-day money-back guarantee . Now is the perfect time to join. We have just released our Top Picks for 2026 , and with the guarantee, you have everything to gain and nothing to lose.Private credit stocks have fallen sharply recently, as evidenced by weakness in publicly traded business development companies (BDCs) ( BIZD ), as well as in alternative asset managers that have heavy concentration in private credit. ForSamuel Smith has a diverse ba ...

VANCOUVER, British Columbia, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Diversified Royalty Corp. (TSX: DIV, DIV.DB.A and DIV.DB.B) (the “Corporation” or “DIV”) is pleased to announce that the underwriters, in respect of its recently completed bought deal public offering (the “Offering”) of $60,000,000 aggregate principal amount of 5.75% convertible unsecured subordinated debentures (the “Debentures”) at a price of $1,000 per Debenture (the “Offering Price”), have fully exercised their previously announced option to ...

About Maravai Maravai is a leading life sciences company providing critical products to enable the development of drug therapies, diagnostics, and novel vaccines and to support research on human diseases. Maravai's companies are leaders in providing products and services in the fields of nucleic acid synthesis and biologics safety testing to many of the world's leading biopharmaceutical, vaccine, diagnostics, and cell and gene therapy companies. SAN DIEGO--(BUSINESS WIRE)--Maravai LifeSciences, Inc. (Marava ...

Group 1 - Melius downgraded Microsoft from Buy to Hold due to increasing competitive threats from AI and rising capital expenditure requirements [1] - Microsoft's 365 business is under pressure from AI-driven competitors, requiring higher capital spending to compete with firms like Alphabet and Amazon [2] - Higher investment levels could negatively impact free cash flow, while insufficient spending may indicate execution challenges or earnings management [2] Group 2 - Concerns were raised about long-term assumptions regarding OpenAI, with doubts about its ability to generate free cash flow compared to competitors like Anthropic and Google [3] - Melius suggested that public investors might push OpenAI towards a less capital-intensive model in the future [3] - Microsoft is currently trading at approximately 49 times FY27 enterprise value to free cash flow, indicating it may be overvalued based on revised estimates [4] Group 3 - Melius lowered its price target for Microsoft to $430 and set Oracle's target at $160, while reiterating a Sell rating on Adobe [4]

It's hard to have any conversation about the stock market without touching on artificial intelligence. ...

New York, New York--(Newsfile Corp. - February 9, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of common stock of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) between August 3, 2023 and December 26, 2025. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than April 6, 2026. SO WHAT: If you purchased Ultragenyx common stock during the Class Period you may be enti ...

PresentationPaul ThwaiteGroup CEO & Executive Director Good morning, everyone, and thank you for joining us at short notice following our announcement of the acquisition of Evelyn Partners. I'm here with Katie. I'll start with a short introduction before we take your questions. With the GBP 2.7 billion acquisition of Evelyn Partners, we are creating the U.K.'s leading private banking and wealth manager. This accelerates delivery of the group strategy by increasing our exposure to a highly attractive growin ...